Sam Brusco, Associate Editor11.16.23
Inari Medical has closed its acquisition of LimFlow, a company focused on limb salvage for patient with chronic limb-threatening ischemia (CLTI).
The deal began at the start of November. Its total upfront consideration of $250 million was paid in cash upon closing, Inari said. Contingent consideration of up to $165 million in additional payments depend on reaching certain commercial and reimbursement milestones, paid out between 2025 and 2027.
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from CLTI,” Inari CEO Drew Hykes told the press. “LimFlow addresses one of the most significant unmet needs in all of vascular medicine, is closely aligned with our mission and adds another highly differentiated growth platform into our portfolio.”
LimFlow recently earned U.S. Food and Drug Administration (FDA) approval for its Transcatheter Arterialization of Deep Veins (TADV) system, based on the results of its PROMISE II study. The results, which were published in the New England Journal of Medicine, showed the LimFlow system achieved 70% improvement in amputation-free survival over the current standard of care.
Inari estimates about 55,000 U.S. patients suffering from CLTI each year have no treatment options other than amputation.
The deal began at the start of November. Its total upfront consideration of $250 million was paid in cash upon closing, Inari said. Contingent consideration of up to $165 million in additional payments depend on reaching certain commercial and reimbursement milestones, paid out between 2025 and 2027.
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from CLTI,” Inari CEO Drew Hykes told the press. “LimFlow addresses one of the most significant unmet needs in all of vascular medicine, is closely aligned with our mission and adds another highly differentiated growth platform into our portfolio.”
LimFlow recently earned U.S. Food and Drug Administration (FDA) approval for its Transcatheter Arterialization of Deep Veins (TADV) system, based on the results of its PROMISE II study. The results, which were published in the New England Journal of Medicine, showed the LimFlow system achieved 70% improvement in amputation-free survival over the current standard of care.
Inari estimates about 55,000 U.S. patients suffering from CLTI each year have no treatment options other than amputation.